iTeos Therapeutics, Inc. financial data

Symbol
ITOS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
321 Arsenal Street, Bldg 312, Floor 3, Suite 301, Watertown, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.5K % -23.5%
Debt-to-equity 14.9 % +15.8%
Return On Equity -20.1 % -107%
Return On Assets -17.5 % -103%
Operating Margin -430 % -206%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.5M shares
Common Stock, Shares, Outstanding 36.5M shares +2.08%
Entity Public Float 380M USD -37.6%
Common Stock, Value, Issued 37K USD +2.78%
Weighted Average Number of Shares Outstanding, Basic 43.1M shares +20.5%
Weighted Average Number of Shares Outstanding, Diluted 43.1M shares +20.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 35M USD -47.4%
Research and Development Expense 136M USD +22.5%
General and Administrative Expense 49.7M USD +1.14%
Operating Income (Loss) -150M USD -61%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -112M USD -93.1%
Income Tax Expense (Benefit) 9.08M USD +156%
Net Income (Loss) Attributable to Parent -121M USD -96.7%
Earnings Per Share, Basic -3.15 USD/shares -82.1%
Earnings Per Share, Diluted -3.15 USD/shares -81%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 124M USD -39.4%
Assets, Current 545M USD -12%
Property, Plant and Equipment, Net 5.37M USD +61.3%
Operating Lease, Right-of-Use Asset 5.51M USD -6.75%
Other Assets, Noncurrent 928K USD +5.7%
Assets 723M USD +6.71%
Accounts Payable, Current 7.15M USD +109%
Employee-related Liabilities, Current 8.31M USD
Accrued Liabilities, Current 943K USD -95.7%
Liabilities, Current 36.8M USD +30.4%
Operating Lease, Liability, Noncurrent 4.17M USD -13.3%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 91.4M USD +15.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -11M USD +17.3%
Retained Earnings (Accumulated Deficit) 33.9M USD -78.1%
Stockholders' Equity Attributable to Parent 632M USD +5.59%
Liabilities and Equity 723M USD +6.71%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -32.4M USD -22%
Net Cash Provided by (Used in) Financing Activities 22K USD -96.2%
Net Cash Provided by (Used in) Investing Activities -69.6M USD -120%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 36.5M shares +2.08%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -105M USD -75.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 124M USD -39.3%
Deferred Tax Assets, Valuation Allowance 74.4M USD +63.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 76.2M USD +61.8%
Operating Lease, Liability 5.53M USD -6.76%
Payments to Acquire Property, Plant, and Equipment 945K USD +694%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -119M USD -89.5%
Lessee, Operating Lease, Liability, to be Paid 6.04M USD -5.39%
Property, Plant and Equipment, Gross 10.3M USD +40.6%
Operating Lease, Liability, Current 1.35M USD +21.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.54M USD +15.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.58M USD +15.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 510K USD +12.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.04M USD -20.7%
Deferred Tax Assets, Operating Loss Carryforwards 21.8M USD +63.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 44.1M USD +10.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 852K USD +3.9%
Operating Lease, Payments 1.48M USD +40.5%
Additional Paid in Capital 609M USD +33.4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.84M USD +8.74%
Share-based Payment Arrangement, Expense 30.1M USD +16.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%